Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab
- PMID: 24003284
- PMCID: PMC3756206
- DOI: 10.5021/ad.2013.25.3.368
Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab
Figures



References
-
- Hu Y, Shen F, Crellin NK, Ouyang W. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann N Y Acad Sci. 2011;1217:60–76. - PubMed
-
- Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339–1350. - PubMed
-
- Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625–2630. - PubMed
-
- Hayashida S, Uchi H, Moroi Y, Furue M. Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. J Dermatol Sci. 2011;61:180–186. - PubMed
-
- Puya R, Alvarez-López M, Velez A, Casas Asuncion E, Moreno JC. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51:115–116. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources